Evidence map›Paper›PMID 39825372›Full record

ArticleClinical epigenetics2025

Hypoxia impairs decitabine-induced expression of HLA-DR in acute myeloid leukaemia cell lines.

Sam Humphries, Sean M Burnard, Courtney D Eggins, Simon Keely, Danielle R Bond, Heather J Lee

RetractedAbstract readRetracted Publication
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Sam HumphriesSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, 2308, Australia.
Sean M BurnardSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, 2308, Australia.
Courtney D EgginsSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, 2308, Australia.
Simon KeelySchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, 2308, Australia.
Danielle R BondSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, 2308, Australia.
Heather J LeeSchool of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, 2308, Australia. heather.lee@newcastle.edu.au.

Funding

Australian Research Council DP200102903Cancer Institute NSW ECF171145National Health and Medical Research Council GNT1180782
6 · The paper itself

Abstract

backgroundHypomethylating agents (HMA), such as azacytidine (AZA) and decitabine (DAC), are epigenetic therapies used to treat some patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome. HMAs act in a replication-dependent manner to remove DNA methylation from the genome. However, AML cells targeted by HMA therapy are often quiescent within the bone marrow, where oxygen levels are low. In this study, we investigate the effects of hypoxia on HMA responses in AML cells.

resultsAML cell lines (MOLM-13, MV-4-11, HL-60) were treated with DAC (100 nM) or AZA (500-2000 nM) in normoxic (21% O

conclusionOur results suggest that HMA-induced antigen presentation may be impaired by hypoxia. This study highlights the need to consider microenvironmental factors when designing co-treatment strategies to improve HMA therapeutic efficacy.

Indexed as

DecitabineHLA-DR AntigensLeukemia, Myeloid, AcuteAntimetabolites, AntineoplasticAzacitidineCell HypoxiaCell Line, TumorDNA MethylationEpigenesis, GeneticGene Expression Regulation, LeukemicHL-60 CellsHumansAntimetabolites, AntineoplasticAzacitidineDecitabineHLA-DR AntigensAcute myeloid leukaemiaHuman leukocyte antigensHypomethylating agentsHypoxia

Identifiers

PMID39825372
PMCPMC11748578

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.